Marian Chu

6 days ago | bioworld.com | Marian Chu

Home » FDA shift from animal testing fuels organoid, organ-on-chip demand BioWorld briefs for May 9, 2025. BioWorld MedTech briefs for May 8, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

1 week ago | bioworld.com | Marian Chu

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...

1 week ago | bioworld.com | Marian Chu

South Korea urges US to exempt pharma, allies from tariffsSouth Korean government and biopharmaceutical industry representatives urged American policymakers May 7 to refrain from imposing tariffs on pharmaceutical imports, and to spare allies if pharma tariffs are deemed necessary.

1 week ago | bioworld.com | Marian Chu

Three Korea biotechs prep for May IPOsAmong three Korean biotech companies slated to sell shares on the Korea Exchange this month, Immuneoncia Therapeutics Inc. is the latest to price a ₩33.9 billion (US$24 million) Kosdaq IPO for May 19. Regenerative cell therapy maker Organoid Sciences Ltd. and antibody-drug conjugate specialist Intocell Inc. are also gearing up for respective Kosdaq listings starting next week.

1 week ago | bioworld.com | Marian Chu

Home » South Korea approves record number of biosimilars in 2024 BioWorld briefs for May 5, 2025. BioWorld MedTech briefs for May 5, 2025. The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If approved, the daily pill will be the... The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...